Author Affiliations: Fuzhou General Hospital, Xiamen University, Fuzhou, Fujian, PR China (Dr Tan; firstname.lastname@example.org); and Diabetes Research Institute and Cell Transplant Center, University of Miami, Miami, Florida (Drs Pileggi and Ricordi).
In Reply: Human MSCs obtained from marrow mononuclear cells were cultured in low-glucose Dulbecco-modified Eagle medium (Gibco-Invitrogen) supplemented with 10% human platelet lysates (Beijing Sino-US Fuxing). Confluent MSCs were detached with 0.05% Trypsin-EDTA (Gibco-Invitrogen).1 Safety measures proposed by the Food and Drug Administration in 2008 for Human Somatic Cell Therapy Investigational New Drug Applications were followed. As discussed, putative MSC identity markers2 were confirmed by flow cytometry prior to each inoculum; also, passage-4 MSCs differentiated in vitro into bona fide mesenchymal tissues (bone, cartilage, fat or muscle).2
Tan J, Pileggi A, Ricordi C. Stem Cell Therapy in Kidney Transplantation—Reply. JAMA. 2012;308(2):130-131. doi:10.1001/jama.2012.6372